Bank of New York Mellon Corp Takes $2.61 Million Position in Replimune Group, Inc. $REPL

Key Points

• Bank of New York Mellon acquired 235,405 Replimune shares worth approximately $2.61 million, giving it a 0.28% stake. Institutional investors collectively own 92.53% of the company.
• Analyst sentiment is generally positive: Replimune has a “Moderate Buy” consensus rating and a $12 average price target, though ratings range from Strong Buy to Sell.
• Replimune opened at $15.04 and recently reported a quarterly loss of $0.72 per share, missing estimates by $0.03. Analysts expect a full-year loss of $2.81 per share.

Bank of New York Mellon Corp purchased a new position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 235,405 shares of the company's stock, valued at approximately $2,606,000. Bank of New York Mellon Corp owned 0.28% of Replimune Group as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in REPL. ProShare Advisors LLC lifted its stake in shares of Replimune Group by 10.3% in the fourth quarter. ProShare Advisors LLC now owns 16,116 shares of the company's stock worth $157,000 after acquiring an additional 1,505 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of Replimune Group by 4.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 38,016 shares of the company's stock valued at $159,000 after purchasing an additional 1,712 shares in the last quarter. Ballentine Partners LLC raised its position in shares of Replimune Group by 7.8% in the 4th quarter. Ballentine Partners LLC now owns 23,665 shares of the company's stock valued at $230,000 after purchasing an additional 1,721 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Replimune Group by 37.5% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company's stock valued at $64,000 after buying an additional 1,879 shares during the last quarter. Finally, Walleye Capital LLC boosted its stake in shares of Replimune Group by 3.2% during the 1st quarter. Walleye Capital LLC now owns 71,592 shares of the company's stock valued at $548,000 after buying an additional 2,192 shares during the last quarter. Institutional investors and hedge funds own 92.53% of the company's stock.

Wall Street Analyst Weigh In

REPL has been the subject of a number of research analyst reports. BMO Capital Markets upgraded shares of Replimune Group from an "underperform" rating to an "outperform" rating and set a $16.00 price target for the company in a research note on Tuesday, June 30th. Weiss Ratings lowered shares of Replimune Group from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday, August 11th. Wedbush upgraded Replimune Group from a "neutral" rating to an "outperform" rating and set a $12.00 price target for the company in a research note on Friday, August 7th. JPMorgan Chase & Co. lifted their price target on Replimune Group from $20.00 to $21.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 26th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Replimune Group in a report on Wednesday, August 12th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Replimune Group currently has a consensus rating of "Moderate Buy" and a consensus target price of $12.00.

Replimune Group Stock Performance

NASDAQ:REPL opened at $15.04 on Tuesday. Replimune Group, Inc. has a 12-month low of $1.50 and a 12-month high of $16.33. The firm has a market capitalization of $1.41 billion, a P/E ratio of -4.77 and a beta of 0.94. The company has a debt-to-equity ratio of 1.00, a current ratio of 5.23 and a quick ratio of 5.23. The business has a 50 day simple moving average of $12.33 and a 200 day simple moving average of $8.66.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its earnings results on Friday, August 14th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.03). Equities research analysts predict that Replimune Group, Inc. will post -2.81 EPS for the current year.

Insiders Place Their Bets

In other Replimune Group news, insider Konstantinos Xynos sold 11,447 shares of the business's stock in a transaction on Monday, August 10th. The stock was sold at an average price of $12.97, for a total transaction of $148,467.59. Following the completion of the transaction, the insider owned 224,215 shares in the company, valued at approximately $2,908,068.55. The trade was a 4.86% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Sushil Patel sold 39,341 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $12.97, for a total value of $510,252.77. Following the completion of the transaction, the chief executive officer directly owned 708,151 shares of the company's stock, valued at approximately $9,184,718.47. The trade was a 5.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 79,124 shares of company stock worth $1,038,364 over the last 90 days. Insiders own 5.40% of the company's stock.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company's proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune's lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.